Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients

Launched by SOUTH VALLEY UNIVERSITY · Feb 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain genetic factors, known as Rab 32 gene polymorphisms, might help predict the outcomes for patients with leprosy, a disease caused by the bacteria Mycobacterium leprae. The trial aims to understand if these genetic variations can provide valuable information about how the disease affects individuals and how well they might respond to treatment.

If you or someone you know has been diagnosed with leprosy and has a positive test result from a skin sample, you might be eligible to participate in this study. The trial is open to adult patients aged 18 to 60, regardless of gender. Participants will receive the standard multi-drug therapy for leprosy and will be monitored throughout the study to see how their condition progresses. It's important to note that individuals who are pregnant, breastfeeding, or have certain allergies to specific medications cannot join the trial. This study not only aims to improve understanding of leprosy but may also contribute to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients of both sexes with positive slit skin smear for m.leprae .
• Exclusion Criteria:
• * Contraindications to Multi drug therapy :
• • Patients with hypersensitivity to sulfa .
• • Patients with hypersensitivity to clofazimine or rifampcin.
• • pregnant or lactating women.